Clinical trial
A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy
NCT00899093 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy
- Lead sponsor
- Gynecologic Oncology Group
- Phase
- Observational
- Overall status
- Terminated
- Start date
- September 30, 2007
- Completion date
- Not reported
- Enrollment
- 2,500 (estimated)
- Sites
- 131
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube adenocarcinoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, malignant ovarian brenner tumor, malignant ovarian clear cell tumor, malignant ovarian endometrioid tumor, malignant ovarian mixed epithelial tumor, malignant ovarian mucinous tumor, malignant ovarian neoplasm, malignant ovarian serous tumor, malignant ovarian transitional cell tumor, ovarian adenocarcinoma, primary peritoneal serous adenocarcinoma, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer, undifferentiated fallopian tube carcinoma, undifferentiated ovarian carcinoma